ID: adamax
Aliases: ADAMAX, Semax-adamantane analog, research nootropic peptide
Type: compound
Route/form: no approved human route; route claims are not established in peer-reviewed human evidence
Status: research
Evidence level: mechanistic
Best data tier: mechanistic/chemistry
Support scope: non-human/mechanistic, review/regulatory
Source types: preclinical, regulatory_safety
Linked sources: 3
Broad outcomes: Brain / mood / sleep
Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.
Targets / mechanism
- Semax/P21-like neurotrophic peptide rationale
- putative BDNF/neurotrophin signaling
- adamantane-linked peptide design hypothesis
Optimization domains
- brain
- nootropic
- neuroprotection
- research peptide
Research basis
- There is preclinical support for related adamantane-neurotrophic peptide designs improving learning, neurogenesis, synaptogenesis, and amyloid-toxicity endpoints.
Limits, risks, and missing evidence
- Direct peer-reviewed Adamax human efficacy evidence was not found in this pass.
Risk flags
- no direct human data found
- identity uncertain
- unapproved context
- neuroactive
Linked papers, labels, and reviews
- Medsafe Medicines Classification Committee: classification of unscheduled peptides including Adamax and P21
regulatory_safety / medsafe_unscheduled_peptides_2025
Regulatory classification context for nootropic/research peptides with limited direct clinical evidence. - Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptogenesis, and inhibit amyloid beta-associated neuronal death
preclinical / sciencedirect_p021_adamantane_2010
Indirect mechanistic anchor for Adamax-style Semax/P021/adapted peptide claims; not direct Adamax efficacy evidence. - The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo
preclinical / pubmed_semax_bdnf_2003
Rat BDNF-expression source for Semax neurotrophin rationale.